Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to the Brain

NCT05588453 is registered in ClinicalTrials.gov with Kari Kendra as lead sponsor.

NCT NCT05588453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05588453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to the Brain
Lead sponsor
Kari Kendra
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 1, 2023
Completion date
April 15, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv cutaneous melanoma ajcc v8, metastatic malignant neoplasm in the brain, metastatic melanoma, pathologic stage iv cutaneous melanoma ajcc v8